Statin therapy in individuals with intermediate cardiovascular risk

Area of Science:

• Cardiology
• Public Health
• Pharmacology

Background:

• Intermediate cardiovascular risk individuals constitute a significant population segment.
• Determining optimal cholesterol targets is critical for this group.
• This study focuses on optimal low-density lipoprotein cholesterol (LDL-C) levels post-statin therapy.

Purpose of the Study:

• To investigate the optimal low-density lipoprotein cholesterol (LDL-C) level in intermediate cardiovascular risk individuals after statin therapy.
• To provide evidence-based recommendations for cholesterol management in this population.
• To analyze the association between post-treatment LDL-C levels and cardiovascular events.

Main Methods:

• Nationwide observational and validation cohort study utilizing Korean National Health Insurance Service and hospital data.
• Inclusion criteria: intermediate cardiovascular risk (≥2 risk factors, excluding diabetes), LDL-C 100-189 mg/dL, new statin users.
• Primary outcome: composite cardiovascular events (myocardial infarction, coronary revascularization, ischemic stroke); follow-up duration: 7.5-8.7 years.

Main Results:

• Lower LDL-C levels (<120 mg/dL) were associated with reduced composite cardiovascular event risk (p=0.001-0.009) in the main cohort.
• In the validation cohort, LDL-C <100 mg/dL showed a more pronounced risk reduction (p=0.006-0.03).
• Total mortality risk did not significantly differ between LDL-C groups.

Conclusions:

• Achieving LDL-C levels <120 mg/dL post-statin therapy is linked to lower cardiovascular event risk in intermediate-risk individuals.
• The findings support <120 mg/dL as a beneficial LDL-C target for this population.
• This study offers clinically relevant insights for optimizing statin therapy and cholesterol management.